IVERIC bio to Participate in Upcoming September Investor / Industry Conferences
September 03 2020 - 8:00AM
Business Wire
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company
will participate in the following upcoming virtual investor
conferences in September:
- Citi 15th Annual BioPharma Virtual Conference 2020 on
Wednesday, September 9 and Thursday, September 10, 2020, IVERIC bio
will host meetings with investors.
- Cantor Virtual Global Healthcare Conference 2020 on
Wednesday, September 16, 2020 at 8:00 a.m. ET, investors and the
general public are invited to listen to a live webcast of a
fireside chat with Glenn P. Sblendorio, Chief Executive Officer and
President and Pravin U. Dugel, M.D., Chief Strategy and Business
Officer, available on the Investors / Events section of the IVERIC
bio website at www.ivericbio.com. An archived replay will be
available on the Company’s website immediately following the
conference and for at least two weeks thereafter.
The Company will also participate in the following retina
showcase:
- Ophthalmology Innovation Summit (OIS) Retina Innovation
Showcase on Thursday, September 10, 2020 at 1:36 p.m. ET. Dr.
Dugel will present an overview of the Company. To listen to the
presentation visit the Investors / Events section of the IVERIC bio
website at www.ivericbio.com.
About IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused
on the discovery and development of novel treatment options for
retinal diseases with significant unmet medical needs. The Company
is currently developing both therapeutic product candidates for
age-related retinal diseases and gene therapy product candidates
for orphan inherited retinal diseases. Vision is Our Mission. For
more information on the Company, please visit
www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about IVERIC bio’s future
expectations, plans and prospects constitute forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Any
forward-looking statements represent IVERIC bio’s views only as of
the date of this press release. IVERIC bio anticipates that
subsequent events and developments will cause its views to change.
While IVERIC bio may elect to update these forward-looking
statements at some point in the future, IVERIC bio specifically
disclaims any obligation to do so.
ISEE-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005119/en/
Investor Contact: IVERIC bio Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com
or
Media Contact: SmithSolve Alex Van Rees, 973-442-1555
ext. 111 alex.vanrees@smithsolve.com
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Mar 2024 to Apr 2024
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Apr 2023 to Apr 2024